US drug makers have imposed big price rises for top selling drugs, study findsBMJ 2016; 353 doi: https://doi.org/10.1136/bmj.i1944 (Published 05 April 2016) Cite this as: BMJ 2016;353:i1944
- Michael McCarthy
From 2011 to 2014 drug companies have increased the prices of four of the top 10 drugs sold in the United States by more than 100% and the prices of the remaining six by more than 50%, an analysis by Reuters has found.1
According to the news agency, the biggest increase was by AbbVie Inc, which raised the price of arthritis drug Humira (adalimumab) by more than 126%. The next highest price increases were by Amgen, maker of the arthritis drug Enbrel (etanercept), and Teva Pharmaceuticals, maker of the multiple sclerosis drug Copaxone (glatiramer acetate). Both companies raised the prices of their drugs by 118%. AstraZeneca came in fourth with a 113% price increase for its cholesterol drug Crestor (rosuvastatin).